Register
Login:
Share:
Email Facebook Twitter

SAR Share Chat - RSS Feed

Sareum Share Chat (SAR)



Share Price: 0.45Bid: 0.40Ask: 0.50Change: 0.00 (0.00%)No Movement on Sareum
Spread: 0.10Spread as %: 25.00%Open: 0.45High: 0.45Low: 0.45Yesterday’s Close: 0.45


Share Discussion for Sareum (SAR)


Thread ViewThread View
Please Login or Register to post messages
Posts per page:


BOOKMAN
Posts: 1,055
Off Topic
Opinion:No Opinion
Price:0.58
View Thread (2)
RE: oh dear
6 Jun '14
ive 1m share at 90 no rush.been here 2011.
 
nickg07
Posts: 302
Off Topic
Opinion:No Opinion
Price:0.58
View Thread (2)
oh dear
6 Jun '14
Someone must be in the hole and is deperate to try and ramp up some business is all i can say?
9crompton
Posts: 929
Off Topic
Opinion:No Opinion
Price:0.58
us news
6 Jun '14
Radius Health Inc., a Cambridge, Mass.-based developer of drug therapies for osteoporosis and women's health, raised $52 million in its IPO. The company priced 6.5 million shares at $8 per share (its downwardly-revised terms), and will trade on the Nasdaq under ticker symbol RDUS. Jefferies and Cowan & Co. served as lead underwriters. Radius Health has raised over $200 million in VC funding from MPM Capital (28% pre-IPO stake), The Wellcome Trust (7.9%), HealthCare Ventures (6.3%), BB Biotech Ventures (6.6%), Saints Capital (5.2%), Nordic Bioscience (12.7%) and Brookside Capital Partners (5.9%). www.radiuspharm.com

Syndax Pharmaceuticals Inc., a Waltham, Mass.-based developer of epigenetic therapies for treatment-resistant cancers, has set its IPO terms to 4.3 million shares being offered at between $13 and $15 per share. It would have an initial market cap of around $171 million, were it to price in the middle of its range. The pre-revenue company plans to trade on the Nasdaq under ticker symbol SNDX, with Deutsche Bank Securities and Jefferies serving as lead underwriters. Shareholders include Domain Associates (34.3% pre-IPO stake), MPM Capital (29.5%), Forward Ventures (8.2%), RusnanoMedInvest (13.2%) and Forward Ventures (8.2%). www.syndax.com

Zafgen Inc., a Cambridge, Mass.-based biopharma company focused on the needs of severely obese patients, has set its IPO terms to five million shares being offered at between $14 and $16 per share. It would have an initial market cap of around $312 million, were it to price in the middle of its range. The pre-revenue company plans to trade on the Nasdaq under ticker symbol ZFGN, with Leerink Partners and Cowen & Co. serving as lead underwriters. Shareholders include Atlas Venture (35.6% pre-IPO stake), Third Rock Ventures (35.4%), Alta Partners (7.4%) and Fidelity Investments (6%). Zafgen also announced the receipt of a $20 million term loan from Oxford Finance and MidCap Financial. www.zafgen.com

ZS Pharma Inc., a Fort Worth, Texas-based developer of treatments for kidney and liver disease, has set its IPO terms to five million shares being offered at between $15 and $17 per share. It would have an initial market cap of around $300 million, were it to price in the middle of its range. The pre-revenue company plans to trade on the Nasdaq under ticker symbol ZSPH, with J.P. Morgan and Credit Suisse serving as lead underwriters. It has raised over $55 million in VC funding from such firms as Alta Partners (22.9% pre-IPO stake), Devon Park Bioventures (17.94%), 3x5 Special Opportunity Partners (16.55%), Salem Partners (12.96%) and RiverVest Venture Partners. www.zspharma.com
BOOKMAN
Posts: 1,055
Off Topic
Opinion:No Opinion
Price:0.58
raise your standards....
6 Jun '14
ITS SUNNY TODAY.LOVELY BUT COULD BE WINTER TOMORROW......SAREUM is about to change........1hr to go
BOOKMAN
Posts: 1,055
Off Topic
Opinion:No Opinion
Price:0.58
HAVE A GOOD WEEKEND
6 Jun '14
what was impossible yesterday is possible today.change is coming .goodluck dyor
BOOKMAN
Posts: 1,055
Off Topic
Opinion:No Opinion
Price:0.58
REMEMBER this
6 Jun '14
what the message here is everything is all still in place....its just taken longer than usual ask yourself WHY...MONEY,
CEO,DEAL,ECONOMY,whatever it is it needs to change we have all invested here to make a quick buck or really care about sareum and what she stands for .

tim on the other hand is passionate about his role and has to make changes with the way he addresses his share holders ,if one way does not work we have to try others I've been posting all week about how this share has jumped 30% on nothing just think what she can do with news.lets look at the BARE FACTS?????
BOOKMAN
Posts: 1,055
Off Topic
Opinion:No Opinion
Price:0.58
18mths late
6 Jun '14
SAREUM TAKES HIT OVER DEALS DELAY
December 12, 2012 Written by {ga=lautaro-vargas} Published in Medtech
Cancer drug developer, Sareum, says it is now unlikely to close its first internal licensing deal before the end of the year, sending its share price down by almost 20 per cent.
The Cambridge-based biotech saw a huge jump in its share price earlier in the year of over 148 per cent after it announced it was in discussions for for the inaugural deal, taking it from 0.63 pence to 1.55p a share. Today's news has brought that back down to 1.40.

However, that's still well above what its price was prior to the first deal announcement. This is in part due to a Standby Equity Distribution Agreement (SEDA) that allows the company to draw down on up to £4m over the next three years

In a company statement, Sareum chairman, Dr Paul Harper, said it had become increasingly apparent that the opportunity of concluding a deal before the calendar year-end is now less likely than was previously anticipated though the board remained confident that a commercial deal with one or more of its programmes would be concluded.

"We remain focused on maximising the opportunities for commercial exploitation however they arise," said Dr Harper. "The addition of the £4 million SEDA financing facility, from which the first tranche of funding was drawn down last week, gives us considerable flexibility in funding further development work, as well as putting us in a strong position to negotiate with collaborators and possible partners."
BOOKMAN
Posts: 1,055
Off Topic
Opinion:No Opinion
Price:0.58
HAPPENING
6 Jun '14
DEAL IN THE AIR AS OVER A BILLION SAREUM SHARES CHANGE HANDS?

Sareum-price
Eyebrows were raised along the Square Mile as over a billion shares in tiny stock, Sareum, changed hands – sending the modest share price shooting up almost 300 per cent to 1.65p.
Sareum, the specialist cancer drug discovery business, announced positive results from pre-clinical in-vivo efficacy studies into acute myeloid leukaemia – the most common form of adult leukaemia.

But analysts were looking deeper. It is rare there is such a shift in sentiment towards a stock of this nature without a sniff of an acquisition in the air. The new success clearly makes Sareum an attractive acquisition target.

A study for Sareum’s Aurora+FLT3 Kinase programme showed that the leukaemia regressed to such an extent that no detectable cancer could be found in any of the cases treated (10 in total) with a Sareum compound.

By comparison, leukaemia increased five to 15 fold in study examples treated without Sareum’s compound. At six weeks following treatment, no detectable cancer could be found in two of the 10 examples dosed with the Sareum compound. In the other eight treated examples the average time taken for the leukaemia to increase five-fold was six weeks, compared to two weeks in the untreated cases.

CEO, Dr Tim Mitchell, said: “The results compare very favourably with those from similar pre-clinical studies published for Aurora kinase inhibitors in clinical trials.

“We look forward to presenting the data to potential licencees. 350,000 people a year are diagnosed with leukaemia; we are pleased to be contributing to the search for a cure for this disease.”
BOOKMAN
Posts: 1,055
Off Topic
Opinion:No Opinion
Price:0.58
View Thread (2)
RE: Bookman
6 Jun '14
guys this share is sparkling and going to make a lot of people happy come news time 70 finish today..

hopkirk.

thats were i got it from what you asked me.galapagos has teamed with sareum the company renowned for fast tracking ..
Hopkirk
Posts: 1,171
Off Topic
Opinion:No Opinion
Price:0.58
View Thread (2)
Bookman
6 Jun '14
That is hardly new news and stems back to when the company was revamped to focus purely on drug discovery, unless I've missed something. ..

http://www.sareum.co.uk/pressreleases.php?newsid=89&year=2008



Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs

Sign up for Live Prices
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.